Company Description

Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis.

Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D).

It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.

Vogenx, Inc.

Country	United States
Founded	2021
IPO Date	Aug 12, 2026
Industry	Biotechnology
Sector	Healthcare
Employees	5
CEO	James Green

Contact Details

Address: 3901 Barrett Drive, Suite 300 Raleigh, North Carolina 27609 United States
Phone	919 659 5677
Website	vogenx.com

Stock Details

Ticker Symbol	VOGX
Exchange	NASDAQ
Stock Type	Common Stock
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$13.00
CIK Code	1903784
CUSIP Number	92859A106
ISIN Number	US92859A1060
Employer ID	86-3697324
SIC Code	2834

Key Executives

Name	Position
James Green	President, Chief Executive Officer and Chairman
Steven R. Delmar	Chief Financial Officer, Corporate Secretary and Director
Dr. William Wilkison Ph.D.	Chief Scientific Officer, Chair of Scientific Advisory Board and Director

Latest SEC Filings

Date	Type	Title
Oct 9, 2026	8-K	Current Report
Sep 22, 2026	8-K	Current Report
Sep 17, 2026	10-Q	Quarterly Report
Sep 8, 2026	SCHEDULE 13G	Filing
Aug 19, 2026	8-K	Current Report
Aug 13, 2026	8-K	Current Report
Aug 13, 2026	S-8	Securities to be offered to employees in employee benefit plans
Aug 12, 2026	424B4	Prospectus
Aug 11, 2026	EFFECT	Notice of Effectiveness
Aug 11, 2026	CERT	Certification by an exchange approving securities for listing

View All SEC Filings